The evaluation of innovation in radiation oncology - What can we do and what should we do?

Acta Oncologica

Volumn 54, Issue 9, 2015, Pages 1251-1253

  Pignol, Jean Philippe ^a   Janus, Cecile ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; GOLD STANDARD; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NOTE; ONCOLOGY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RECTUM CANCER; XEROSTOMIA; NEOPLASMS; PROCEDURES;

HUMANS; NEOPLASMS; RADIATION ONCOLOGY;

EID: 84944870868     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1067719     Document Type: Note

References (16)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.
2. Smith BD, Pan IW, Shih YC, Smith GL, Harris JR, Punglia R, et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 2011; 103: 798-809.
3. Bentzen SM, Wasserman TH. Balancing on a knife's edge: Evidence-based medicine and the marketing of health technology. Int J Radiat Oncol Biol Phys 2008; 72: 12-4.
4. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010; 22: 643-57.
5. Kontaxis C, Bol GH, Lagendijk JJ, Raaymakers BW. Towards adaptive IMRT sequencing for the MR-linac. Phys Med Biol 2015; 60: 2493-509.
6. Baumert BG, Norton IA, Lomax AJ, Davis JB. Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions. Int J Radiat Oncol Biol Phys 2004; 60: 1314-24.
7. Langreth R. Prostate cancer therapy too good to be true explodes health cost. [cited 2015 May 15]. Available from: http://www.bloomberg.com/news/articles/2012-03-26/prostate-cancer-therapy-too-good-to-be-true-explodes-health-cost
8. Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008; 26: 2085-92.
9. Available from: http://seer.cancer.gov/statfacts/ [cited 2015 Jun 15].
10. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987; 317: 141-5.
11. Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach. Radiother Oncol 2013; 107: 267-73.
12. Mukesh MB, Harris E, Collette S, Coles CE, Bartelink H, Wilkinson J, et al. Normal tissue complication probability (NTCP) parameters for breast fibrosis: Pooled results from two randomised trials. Radiother Oncol 2013; 108: 293-8.
13. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-98.
14. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74.
15. DErrico MP, Grimaldi L, Petruzzelli MF, Gianicolo EA, Tramacere F, Monetti A, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys 2012; 82: e239-46.
16. Wieshammer S, Dreyhaupt J, Basler B. Elevated levels of N-terminal pro-brain natriuretic peptide in patients with chronic dyspnea and moderate renal dysfunction: Decreased clearance or increased cardiac stress? Cardiorenal Med 2011; 1: 156-63.